S-1/A: Cortigent Files S-1/A for IPO, Targets Vision & Stroke Recovery

Cortigent, a pre-revenue neurostimulation company, files for an initial public offering to fund the development of its Orion artificial vision and Stroke Recovery Systems, despite ongoing operating losses and going concern doubts.

Summary

• Cortigent, a spin-off from Vivani Medical, Inc. (formerly Second Sight Medical Products, Inc.), is pursuing an Initial Public Offering (IPO) of 1,500,000 shares of common stock at an anticipated price of $10.00 per share.
• The company aims to raise approximately $12,920,000 in net proceeds, or $14,990,000 if underwriters exercise their over-allotment option in full.
• Proceeds are primarily allocated to Orion research studies ($3 million), manufacturing for clinical trials ($4 million), Orion pivotal trial preparation ($1 million), repayment of $1.5 million to parent Vivani, and general working capital.
• Cortigent is developing the Orion Visual Cortical Prosthesis System for artificial vision, targeting 82,000 profoundly blind Americans, with an estimated U.S. total addressable market (TAM) of ~$4 billion.
• The Orion system received FDA Breakthrough Device designation in 2018 and completed a 6-year Early Feasibility Study (EFS) in March 2025, showing significant improvement in visual function measures (square localization, direction of motion, grating visual acuity) for remaining subjects.
• A single serious adverse event (SAE), a seizure, occurred in one Orion EFS patient in June 2018, which resolved safely after adjusting stimulation frequencies.
• Cortigent is also developing a Stroke Recovery System to improve arm and hand function in partially paralyzed stroke patients, targeting 195,000 U.S. stroke victims annually, with an estimated U.S. TAM of ~$6 billion.
• The company has a substantial intellectual property estate with rights to 161 issued U.S. patents and 14 issued European patents as of December 31, 2025, with some extending into 2038.
• Cortigent is a pre-revenue company with a history of recurring operating losses, reporting net losses of $2.1 million for the nine months ended September 30, 2025, $2.2 million for 2024, and $5.5 million for 2023.
• As of September 30, 2025, Cortigent had cash and cash equivalents of $394,000 and a working capital deficit of $(3,856,000).
• The company's financial statements are prepared on a going concern basis, with management acknowledging substantial doubt about its ability to continue as a going concern.
• Vivani Medical, Inc. will remain the controlling shareholder, owning approximately 77% of voting power post-IPO (74% if over-allotment option is fully exercised), making Cortigent a 'controlled company' under NYSE standards.
• Cortigent currently employs six full-time persons as of December 31, 2025, after staff reductions to decrease operating expenses.

Sentiment

Score: 3

Explanation: The company is in a highly speculative pre-revenue stage with significant ongoing losses and explicit 'going concern' doubts. While product development shows promise and addresses large markets, the long timelines, substantial future funding needs, and regulatory setbacks (e.g., stroke device BDD denial) present considerable financial and operational risks. The IPO is critical for survival and advancing products, but the inherent uncertainties of medical device development, especially for complex implants, weigh heavily on the sentiment.

Positives

• Orion Visual Cortical Prosthesis System received FDA Breakthrough Device designation in 2018, which is intended to accelerate development and review.
• The Orion Early Feasibility Study (EFS) completed in March 2025 showed positive efficacy results, with 5 of 6 subjects at 36 months and 3 of 6 subjects at 60 months performing significantly better on visual function tasks with the system on.
• All four patients who completed the FLORA evaluation at 36 months had positive or mildly positive results, indicating the Orion system was providing benefit in day-to-day functionality.
• Cortigent possesses an extensive intellectual property estate with rights to 161 issued U.S. patents and 14 issued European patents, with some core technology patents extending into 2038.
• The company is targeting large addressable markets: an estimated $4 billion U.S. TAM for Orion (82,000 patients) and an estimated $6 billion U.S. TAM for the Stroke Recovery System (195,000 patients).
• The neurostimulation platform technology has multiple potential applications beyond vision and stroke recovery, suggesting future growth opportunities.
• The company's predecessor, Second Sight, successfully navigated the FDA approval process for a Class III device (Argus II), demonstrating regulatory experience.

Negatives

• Cortigent is a pre-revenue company with a history of recurring operating losses since inception, and expects losses to continue for the foreseeable future.
• The company's financial condition creates substantial doubt about its ability to continue as a going concern, as noted in its financial statements.
• Cortigent will require substantial additional capital beyond the IPO proceeds to fund clinical trials and growth plans, and there is no assurance such capital will be available on acceptable terms.
• The Stroke Recovery System was denied Breakthrough Device designation by the FDA in June 2023, which may lead to slower interactions and delayed development timelines.
• Approximately 100 of the company's 161 issued U.S. patents will reach the end of their term by the end of 2029, potentially reducing intellectual property protection.
• The company has limited manufacturing experience and will need to establish reliable, efficient, full-scale manufacturing for commercial distribution, which could be costly and delay production.
• Vivani Medical, Inc. will remain a controlling shareholder post-IPO (77% voting power), which may result in interests that differ from other stockholders and could deter beneficial actions or affect stock price.

Risks

• Cortigent currently has no commercial products or product revenue and may never become profitable.
• Commercial and financial success depends on future products being accepted in the market, which is uncertain.
• Substantial competition is expected from major medical device companies, academic institutions, and research institutions, with a risk of not keeping pace with rapid technological changes.
• Results from limited initial trials (Orion EFS) may not be predictive of future trial results, and commercial feasibility is not yet demonstrated.
• Clinical development of complex implantable medical devices is lengthy, expensive, and has an uncertain outcome, with potential for delays or failure at any stage.
• Interim clinical trial results may change as more patient data become available and are subject to audit and verification, potentially leading to material changes in final data.
• Substantial additional capital is required for clinical trials and growth plans, and if unavailable on acceptable terms, could hamper growth and adversely affect the business.
• Issuing future equity or debt securities could dilute existing stockholders and new securities may have senior rights.
• The company may be subject to litigation, governmental investigations, and enforcement actions, which could result in substantial costs, reputational harm, or operational changes.
• The COVID-19 pandemic has adversely affected business and clinical trials, and its continued repercussions could impact demand, operations, and funding.
• Materials necessary for manufacturing products may not be available on commercially reasonable terms or at all, potentially delaying development and increasing costs.
• Failure to recruit and retain highly skilled personnel could impair the ability to develop and commercialize new products.
• Inability to protect intellectual property or challenges to patent validity could adversely affect financial condition and competitive position.
• Third-party claims of intellectual property infringement could prevent or delay development and commercialization activities.
• Reliance on government funding and collaborations may impose requirements that increase development, commercialization, and production costs, and such funding is not assured.
• Dependence on sophisticated information technology systems and third-party vendors carries risks of data integrity failure, cybersecurity breaches, or product malfunction.
• Product liability lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential, especially given the lack of product liability insurance currently.
• Legislative or regulatory reform of the healthcare system in the U.S. and foreign jurisdictions may adversely impact business, operations, or financial results, particularly regarding pricing and reimbursement.
• Stringent domestic and foreign medical device regulations, including ongoing compliance requirements and inspections, could lead to restrictions, suspensions, or revocation of product clearances/approvals.
• Lack of large-scale manufacturing experience could limit growth and impact product quality and sales.
• The price of common stock may be volatile, and there is no prior public market, leading to potential decline after the offering.
• Management has broad discretion in the use of IPO proceeds, which may differ from investor expectations.
• New investors will experience immediate and substantial dilution due to the difference between IPO price and pro forma net tangible book value per share.
• The company has the right to issue preferred stock without stockholder approval, which could adversely affect common stock rights and have anti-takeover effects.
• As a 'controlled company' under NYSE rules, Cortigent intends to rely on exemptions from certain corporate governance standards, potentially reducing protections for stockholders.
• Geopolitical instability (e.g., Russia-Ukraine, Israel-Hamas conflicts) could adversely affect the global economy and financial markets, impacting the company's business and funding.

Future Outlook

Cortigent plans to commence a pivotal clinical trial for the Orion system in mid-2027, aiming for completion by mid-2029 and a U.S. launch in late 2029, assuming FDA clearance. For the Stroke Recovery System, an Early Feasibility Study is targeted for mid-2027, with a pivotal trial in late 2028, completion by mid-2030, and a potential launch in late 2030. These timelines are contingent on adequate financing and FDA collaboration. The company expects to incur additional operating losses for the foreseeable future and will require substantial additional capital to fund these development programs.

Management Comments

• "We believe our 20-year history in developing neurostimulation for artificial vision with the Argus II system positions us well for expanded neurostimulation applications such as Orion and the stroke recovery system."
• "We believe that our 60-channel cortical stimulation device has the potential to target neuron populations more precisely and generate favorable clinical results [for stroke recovery]."
• "We believe that about one-third of these patients [for Orion] could be reached by a marketing program."
• "We believe that outside the United States there are substantially more blind people who could potentially benefit from Orion in Europe, Asia, and the rest of the world."
• "The timeline presented represents managements estimate of the time required to complete each stage. No assurance can be given that these timelines will prove correct."
• "Management has determined that the limited amounts of cash on hand raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued."

Industry Context

Cortigent operates in the highly competitive and rapidly evolving medical device industry, specifically in neurostimulation for vision restoration and stroke rehabilitation. While the Orion system currently has no direct FDA-approved competitors for broad blindness causes, other companies like Pixium Vision SA (now Science Corp.), Bionic Vision Technologies, Illinois Institute of Technology (ICVP), ReVision, and Neuralink Corp. are developing competing visual prostheses, some with penetrating brain electrodes. In stroke rehabilitation, MicroTransponder Inc. sells the FDA-approved Vivistim Vagus Nerve Stimulator (VNS), which combines with traditional therapy. Cortigent believes its targeted cortical stimulation for stroke recovery could offer superior results compared to VNS. The industry is characterized by significant R&D, high capital requirements, and stringent regulatory hurdles, with many academic and private institutions also contributing to research.

Comparison to Industry Standards

• Orion's FDA Breakthrough Device designation is a positive signal, similar to designations received by Illinois Institute of Technology's ICVP and Neuralink's BlindsightTM, indicating potential for accelerated review compared to standard Class III device pathways.
• The Argus II system, Cortigent's predecessor product, achieved FDA approval under a Humanitarian Device Exemption (HDE) and Medicare reimbursement at $150,000 per device, setting a precedent for potential reimbursement levels for Orion, which is targeted at a market 20 times larger.
• Northstar Neuroscience, Inc. previously conducted Phase 1 and 2 clinical studies for a single-channel cortical stimulation device for stroke recovery with positive results, but its pivotal Phase 3 study failed to achieve statistical significance at the primary endpoint, leading to its dissolution. Cortigent believes its 60-channel device offers more precise targeting and potential for better clinical outcomes.
• Competitors like Pixium Vision SA (now Science Corp.) are developing sub-retinal implants (PRIMA) for Dry-AMD, with Science Corp. filing for EU approval in June 2025, indicating active development in the broader artificial vision space, though with different target etiologies and implant locations.
• Bionic Vision Technologies (Australia) has completed a two-year feasibility study in seven patients for its Bionic Eye Visual Prosthesis System and is planning a pivotal clinical trial, representing another competitor in the visual prosthesis market.
• Neuralink Corp. has demonstrated penetrating electrode cortical implants in animal models and has implanted 12 patients with its BCI device (N1) for controlling external devices, with vision restoration (BlindsightTM) as a stated goal, representing a significant, well-funded competitor in brain-computer interfaces that could overlap with Cortigent's long-term vision.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not party to any material legal proceedings.
• May be involved in legal proceedings or subject to claims incident to the ordinary course of business in the future.
• Vivani has chosen to indemnify Cortigent for certain claims from the former business (Second Sight) before August 30, 2022.

Related Party Transactions

• Cortigent was formed in November 2022 as a wholly owned subsidiary of Vivani Medical, Inc. (formerly Second Sight Medical Products, Inc.).
• Vivani contributed all of Second Sight's neurostimulation assets and operations to Cortigent in December 2022.
• Vivani guaranteed the lease for Cortigent's headquarters office space, effective March 1, 2023.
• A Transition Funding, Support and Services Agreement was entered into in March 2023 (amended August 2023) where Vivani advanced funds and provided services to Cortigent, covering salaries, rent, and overhead until December 31, 2024, and continuing until IPO completion.
• Cortigent is required to repay $1.5 million to Vivani from IPO proceeds and issue a five-year promissory note for $2 million at 5% annual interest upon maturity, for a total of $3.5 million owed to Vivani.
• Vivani agreed that Cortigent is not obligated to repay funding support payments exceeding a cumulative $3.5 million.
• Vivani provides services of its Chief Operating Officer (Truc Le) and Chief Business Officer (Donald Dwyer) to Cortigent on an interim basis.
• Cortigent provides services of its Chief Financial Officer (Edward Sedo) to Vivani, with mutual acknowledgment that services provided before IPO completion are equivalent in value and offset each other.
• Vivani will remain the controlling stockholder, owning approximately 77% of Cortigent's voting power post-IPO (74% if over-allotment exercised).
• A master separation agreement will provide that Cortigent will not take certain actions (e.g., incurring indebtedness, acquiring/disposing assets above certain amounts) without Vivani's prior written consent as long as Vivani owns at least 50% of voting power.
• Vivani has agreed to a 12-month lock-up period on its shares post-IPO.

Stakeholder Impact

• **Shareholders (Existing & New):** Existing shareholders (Vivani) will retain majority control, potentially influencing corporate decisions. New investors will experience immediate and substantial dilution. The stock price may be volatile due to pre-revenue status, reliance on future funding, and long development timelines. The 'going concern' doubt poses a significant risk to investment value.
• **Employees:** The company has reduced staff to six full-time employees. Future growth and success depend on attracting and retaining highly skilled personnel, which may be challenging given the company's financial situation and competitive industry. Stock options are planned for officers, directors, and consultants post-IPO.
• **Customers (Future Patients):** Potential customers for Orion (profoundly blind individuals) and the Stroke Recovery System (stroke patients with motor impairment) stand to benefit from novel neurostimulation therapies, but commercial availability is years away and subject to successful clinical trials and regulatory approvals.
• **Suppliers/Contract Manufacturers:** The company relies on sole-source suppliers for critical components and plans to engage two U.S.-based CMOs for manufacturing. Delays or issues with these relationships could impact product development and production.
• **Creditors:** Vivani Medical, Inc. is a significant creditor, with $3.5 million owed, of which $1.5 million will be repaid from IPO proceeds and $2 million via a promissory note. The 'going concern' doubt indicates risk for future creditors.

Next Steps

• Complete the Initial Public Offering (IPO) and list common stock on NYSE American under the symbol CRGT.
• Manufacture and validate new Orion devices for a planned pivotal clinical trial.
• Work with the FDA to gain agreement on additional clinical studies and safety endpoints for Orion.
• Commence the Orion pivotal clinical trial in mid-2027, expecting completion by mid-2029.
• Seek FDA clearance for Orion and launch in the U.S. in late 2029 if successful.
• Manufacture modified clinical trial devices for the Stroke Recovery System's Early Feasibility Study (EFS).
• Commence the Stroke Recovery System EFS in mid-2027.
• Reapply for Breakthrough Device designation for the Stroke Recovery System once clinical data are acquired.
• Commence a pivotal clinical trial for the Stroke Recovery System in late 2028, expecting completion by mid-2030.
• Launch the Stroke Recovery System in late 2030 if successful.
• Submit a new NIH grant application in early 2026 for the stroke recovery program.
• Engage two U.S.-based contract manufacturing organizations (CMOs) for Orion and stroke recovery system production after the offering.
• Hire additional staff to support new product development and clinical trials.
• Conduct pricing and reimbursement market research for Orion and the Stroke Recovery System.
• Complete the Orion patient preference information (PPI) study to assist in determining safety endpoints.

Key Dates

Recommendation

Cortigent is a pre-revenue company with a history of significant operating losses and an explicit 'going concern' warning from management and auditors. While its neurostimulation technology for artificial vision and stroke recovery shows promise and targets large markets, commercialization is years away, highly uncertain, and dependent on substantial future capital raises. The denial of Breakthrough Device designation for the stroke system and the expiration of a large portion of its patent estate by 2029 add to the risk profile. The immediate and substantial dilution for new investors, coupled with the inherent volatility of medical technology stocks and the controlling interest of Vivani, makes this a highly speculative investment with a very high degree of risk. A seasoned investor would likely avoid this offering or consider it a 'strong sell' due to the severe financial distress and long, uncertain path to profitability.

Keywords

Neurostimulation, Artificial Vision, Stroke Recovery, Brain Implant, Medical Device, IPO, SEC Filing, Orion System, Cortical Prosthesis, FDA Breakthrough Device, Clinical Trials, Biotechnology, Healthcare, Neuromodulation